UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM	8-K
-------------	-----

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): May 19, 2022 (May 16, 2022)

SOTERA HEALTH COMPANY

(Exact Name of Registrant as Specified in Charter)

Delaware (State or Other Jurisdiction of Incorporation) 001-39729 (Commission File Number) 47-3531161 (IRS Employer Identification No.)

9100 South Hills Blvd, Suite 300 Broadview Heights, Ohio 44147 (Address of Principal Executive Offices) (Zip Code)

 $(440)\ 262\text{-}1410$ (Registrant's telephone number, including area code)

Not Applicable (Former name or former address, if changed since last report

(Former nam	te or former address, it changed since last re	porti	
Check the appropriate box below if the Form 8-K filing owing provisions (see General Instruction A.2. below):	g is intended to simultaneously satisfy	the filing obligation of the registrant under any of the	
Written communications pursuant to Rule 425 under the	e Securities Act (17 CFR 230.425)		
Soliciting material pursuant to Rule 14a-12 under the E	Exchange Act (17 CFR 240.14a-12)		
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))			
Pre-commencement communications pursuant to Rule	13e-4(c) under the Exchange Act (17	CFR 240.13e-4(c))	
Securities registered pursuant to Section 12(b) of the Act:			
Title of Each Class	Trading Symbol	Name of Exchange on which registered	
Common stock, \$0.01 par value per share	SHC	The Nasdaq Stock Market LLC	
		405 of the Securities Act of 1933 (17 CFR 230.405) or	
		Emerging growth company \square	
	Check the appropriate box below if the Form 8-K filing owing provisions (see General Instruction A.2. below): Written communications pursuant to Rule 425 under the Soliciting material pursuant to Rule 14a-12 under the E Pre-commencement communications pursuant to Rule Pre-commencement communications pursuant to Rule arities registered pursuant to Section 12(b) of the Act: Title of Each Class Common stock, \$0.01 par value per share cate by check mark whether the registrant is an emerging at 12b-2 of the Securities Exchange Act of 1934 (17 CFR) are emerging growth company, indicate by check mark if the	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 pricing registered pursuant to Section 12(b) of the Act: Title of Each Class Trading Symbol	

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On May 16, 2022, Scott J. Leffler, who is currently Chief Financial Officer and Treasurer, informed Sotera Health Company (the "Company") of his decision to resign from his position at the Company to pursue other opportunities and to relocate to Florida for personal reasons. Mr. Leffler will depart from the Company on or about August 12, 2022, and he will remain in his position to assist with the transition of his responsibilities until such date. Mr. Leffler's decision to resign from the Company was not the result of any disagreement relating to the Company's strategy, operations, policies or practices or any issues regarding the Company's accounting policies, procedures, estimates or judgments.

Item 7.01 Regulation FD Disclosure

On May 19, 2022, the Company issued a press release in connection with the foregoing, a copy of which is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

No.	<u>Description</u>
99.1	Press Release, dated May 19, 2022.

104 Cover Page Interactive Data file (formatted as Inline XBRL).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 19, 2022

Sotera Health Company

By: /s/ Terrence G. Hammons, Jr.

Terrence G. Hammons, Jr. Senior Vice President, General Counsel and Secretary



Sotera Health Announces Departure of Chief Financial Officer Scott Leffler

CLEVELAND, Ohio, May 19, 2022 – Sotera Health Company (NASDAQ: SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, today announced the departure of Scott Leffler, Sotera Health's Chief Financial Officer (CFO). After over five years at Sotera Health, Leffler has accepted another CFO role and will be relocating to Florida. To support an orderly transition, Leffler will remain at Sotera Health until August 12, 2022.

Sotera Health has launched a formal search process to identify Leffler's permanent replacement. Mr. Leffler's departure is driven by other opportunities and his family's desire to relocate and is not related to any matter connected with the Company's operations, policies or practices.

"The Board and I thank Scott for his many contributions to Sotera Health during his tenure. He has been an integral part of our executive management team, and we wish him all the best success in his next endeavor," said Michael B. Petras, Jr., Chairman and CEO. "Scott will be working closely with our experienced Finance team on the transition, until his departure in August. We are confident in our ability to execute our business strategy and in the continued growth of the company."

"I am immensely proud of our achievements since I joined Sotera Health over five years ago," said Leffler. "It has been an honor to work with the Sotera Health leadership team and so many exceptionally talented individuals as we grew the company and delivered on our mission, Safeguarding Global Health, while becoming a public company. I am leaving knowing that Sotera Health is well positioned for the future."

About Sotera Health

Sotera Health Company is a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry. Sotera Health goes to market through three businesses – Sterigenics®, Nordion® and Nelson Labs®. Sotera Health is committed to its mission, Safeguarding Global Health®.

INVESTOR RELATIONS CONTACTS

Joseph Vitale VP, Investor Relations, Sotera Health IR@soterahealth.com Sally J. Curley, IRC Curley Global IR, LLC <u>IR@soterahealth.com</u>

MEDIA CONTACT

Kristin Gibbs Chief Marketing Officer, Sotera Health kgibbs@soterahealth.com

Source: Sotera Health Company

###